The U.S. Food and Drug Administration released final guidance for developing, distributing, and labeling mobile health apps used alongside prescription medicines. This guidance provides recommendations on when app content is subject to FDA submission requirements and when an app should be mentioned on a drug’s official label.
Mobile apps play a growing role in managing medications and health conditions, according to local reports. Captain Chris Wheeler, Director of the Division of Medical Policy Programs, stated that this guidance ensures the information these tools provide is accurate, evidence-based, and clearly communicated to patients and providers.
The guidance addresses key questions for industry, including when app content is treated as FDA-required labeling versus promotional labeling. It identifies two categories of companion software: apps connected to a medical device and standalone apps, such as symptom trackers or health coaching tools.
Apps connected to a medical device should be described on the drug’s official prescribing label, given their central role in using the medicine. Standalone apps should appear on the prescribing label if they are essential for safe and effective use or demonstrate a meaningful clinical benefit.
Michael Davis, Director of the FDA’s Center for Drug Evaluation and Research, said this guidance reflects the FDA’s commitment to responsible oversight of digital health. By aligning their approach across drug and device centers, developers have a clear pathway to bring safe, effective digital health technologies to patients.
The FDA’s Jared Seehafer noted that companion apps are moving beyond simple dose reminders toward adaptive tools. Finalizing this guidance gives drug companies and technology partners a stable foundation to build on as these technologies advance.
The guidance aims to reduce unnecessary uncertainty for developers and manufacturers while preserving safety and effectiveness standards. They provide clear recommendations for both drug-connected software and standalone software, making it easier for companies to create and distribute mobile health apps.
The final guidance is available for reference, and it will help companies understand when an app needs to be mentioned on a drug’s official label. Captain Chris Wheeler and his team worked to create a clear and full guide for the industry, and the FDA is committed to continuing its work in this area.
Leave a Reply